Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash & Equivalents (2021 - 2025)

Amylyx Pharmaceuticals has reported Cash & Equivalents over the past 5 years, most recently at $226.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $226.7 million for Q4 2025, up 192.86% from a year ago — trailing twelve months through Dec 2025 was $226.7 million (up 192.86% YoY), and the annual figure for FY2025 was $226.7 million, up 192.86%.
  • Cash & Equivalents for Q4 2025 was $226.7 million at Amylyx Pharmaceuticals, up from $225.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for AMLX hit a ceiling of $247.8 million in Q2 2023 and a floor of $50.2 million in Q4 2021.
  • Median Cash & Equivalents over the past 5 years was $107.7 million (2022), compared with a mean of $119.4 million.
  • Biggest five-year swings in Cash & Equivalents: soared 267.38% in 2023 and later tumbled 69.73% in 2024.
  • Amylyx Pharmaceuticals' Cash & Equivalents stood at $50.2 million in 2021, then rose by 24.58% to $62.5 million in 2022, then soared by 172.21% to $170.2 million in 2023, then crashed by 54.53% to $77.4 million in 2024, then surged by 192.86% to $226.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $226.7 million (Q4 2025), $225.2 million (Q3 2025), and $58.1 million (Q2 2025) per Business Quant data.